A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma

Summary

The study is being conducted to evaluate the safety and tolerability of SHR-3079, and to explore the Dose-limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of SHR-3079 in patients with B-cell non-Hodgkin lymphoma.

Timeline

Start

2026-06

Primary completion

2027-12

Completion

2028-12

Drugs

Indications